Replimune Group (NASDAQ:REPL) Given New $21.00 Price Target at JPMorgan Chase & Co.

Replimune Group (NASDAQ:REPL) had its price target raised by stock analysts at JPMorgan Chase & Co. from $20.00 to $21.00 in a note issued to investors on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 38.29% from the stock’s previous close.

A number of other research analysts also recently commented on the company. Leerink Partners raised Replimune Group from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $11.00 to $17.00 in a research note on Tuesday, August 4th. Piper Sandler upgraded shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 31st. Wall Street Zen raised shares of Replimune Group from a “strong sell” rating to a “sell” rating in a report on Saturday, May 23rd. Wolfe Research raised shares of Replimune Group to an “outperform” rating in a report on Tuesday, August 4th. Finally, Weiss Ratings cut shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $12.00.

Replimune Group Price Performance

Replimune Group stock opened at $15.19 on Wednesday. The stock’s fifty day moving average price is $11.51 and its two-hundred day moving average price is $8.17. Replimune Group has a one year low of $1.50 and a one year high of $15.89. The company has a debt-to-equity ratio of 1.00, a current ratio of 5.23 and a quick ratio of 5.23. The firm has a market cap of $1.42 billion, a PE ratio of -4.85 and a beta of 0.88.

Replimune Group (NASDAQ:REPL) last released its earnings results on Friday, August 14th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.03). As a group, research analysts expect that Replimune Group will post -2.94 EPS for the current fiscal year.

Insiders Place Their Bets

In other Replimune Group news, insider Christopher Sarchi sold 12,000 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $9.24, for a total transaction of $110,880.00. Following the completion of the transaction, the insider owned 180,962 shares of the company’s stock, valued at approximately $1,672,088.88. The trade was a 6.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Konstantinos Xynos sold 11,447 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $148,467.59. Following the completion of the transaction, the insider directly owned 224,215 shares of the company’s stock, valued at $2,908,068.55. This trade represents a 4.86% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 91,124 shares of company stock valued at $1,149,244 over the last ninety days. 5.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Replimune Group

Institutional investors have recently added to or reduced their stakes in the stock. AXQ Capital LP lifted its holdings in shares of Replimune Group by 4.1% during the second quarter. AXQ Capital LP now owns 27,121 shares of the company’s stock worth $300,000 after purchasing an additional 1,056 shares during the period. ProShare Advisors LLC increased its holdings in Replimune Group by 10.3% in the fourth quarter. ProShare Advisors LLC now owns 16,116 shares of the company’s stock valued at $157,000 after purchasing an additional 1,505 shares during the period. JPMorgan Chase & Co. increased its holdings in Replimune Group by 4.7% in the third quarter. JPMorgan Chase & Co. now owns 38,016 shares of the company’s stock valued at $159,000 after purchasing an additional 1,712 shares during the period. Ballentine Partners LLC raised its position in Replimune Group by 7.8% during the 4th quarter. Ballentine Partners LLC now owns 23,665 shares of the company’s stock worth $230,000 after purchasing an additional 1,721 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its position in Replimune Group by 37.5% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock worth $64,000 after purchasing an additional 1,879 shares during the last quarter. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.